Abemaciclib received its first FDA approval in September 2017, following the MONARCH-1 trial [44], as a single agent for women and men with ER-positive, HER2-negative advanced BC after disease progression following endocrine therapy and prior chemotherapy. This evidence concerns the gene ESR1 and breast cancer.